Company Overview - Oupeng Vision (SZ 300595) announced on December 8 that its fourth board meeting was held via communication, discussing the proposal for the reappointment of the accounting firm [1] - As of the report, Oupeng Vision has a market capitalization of 13.9 billion yuan [1] Revenue Composition - For the year 2024, Oupeng Vision's revenue composition is as follows: - Rigid contact lenses account for 56.18% - Medical industry contributes 20.04% - Other optometry and professional services make up 19.47% - Non-optometry and others represent 4.31% [1]

Company Overview - Opcon Vision (SZ 300595) announced on December 5 that it received the "Drug Clinical Trial Approval Notification" from the National Medical Products Administration for its "Pilocarpine Hydrochloride Eye Drops" to conduct clinical trials [1] - As of the report date, Opcon Vision has a market capitalization of 14 billion yuan [1] Revenue Composition - For the year 2024, the revenue composition of Opcon Vision is as follows: - Rigid contact lens industry accounts for 56.18% - Medical industry accounts for 20.04% - Other optometry and professional services account for 19.47% - Non-optometry and others account for 4.31% [1]

Group 1 - The core point of the article is that Opcon Vision has received a Class III medical device registration certificate for its new product, "soft hydrophilic contact lens," from the National Medical Products Administration of China [1] - Opcon Vision's revenue composition for the year 2024 is as follows: 56.18% from rigid corneal contact lenses, 20.04% from the medical sector, 19.47% from other optometry and professional services, and 4.31% from non-optometry and others [1] - As of the report, Opcon Vision has a market capitalization of 14.4 billion yuan [1]